Discovery of substituted benzyl tetrazoles as histamine H3 receptor antagonists
Adam J. Davenport(Evotec (United Kingdom)), David J. Hallett(Evotec (United Kingdom)), Christopher C. Stimson(Evotec (United Kingdom)), Timothy D. Jones(Evotec (United Kingdom)), Darshan G. Vaidya(Evotec (United Kingdom)), Massimo Corsi, Ulrike Fritz(Evotec (Germany)), Sarah Bailey(Evotec (United Kingdom)), Edward P. Glenn(University of Arizona), Mark J. Gemkow(Evotec (Germany))
Cited by 8
Related Papers
The histamine H3 receptor as a therapeutic drug target for CNS disorders
|Drug Discovery Today|2009|181
Distribution and Abundance of Saltcedar and Russian Olive in the Western United States
|Critical Reviews in Plant Sciences|2011|109
Eliapixant is a selective P2X3 receptor antagonist for the treatment of disorders associated with hypersensitive nerve fibers
|Scientific Reports|2021|68
Chiral pyridylimidazolines: synthesis, arene ruthenium complexes and application in asymmetric catalysis
|Journal of the Chemical Society Perkin Transactions 1|2001|67
Arene ruthenium complexes with pyridyloxazolines: synthesis and applications as asymmetric catalysts for Diels–Alder reactions †
|Journal of the Chemical Society Dalton Transactions|2000|66